Safety and efficacy of TNF[alpha] blockade in relapsing vasculitis

Blockade of tumour necrosis factor alpha (TNFα) using infliximab, a chimeric monoclonal antibody against TNFα, is an effective treatment in rheumatoid arthritis and Crohn's disease. 1, 2 Sifikakis reported success using infliximab in sight threatening Behcet's disease. 3 A preliminary st...

Full description

Saved in:
Bibliographic Details
Published in:Annals of the rheumatic diseases 2002-06, Vol.61 (6), p.559
Main Authors: Booth, A D, Jefferson, H J, Ayliffe, W, Andrews, P A, Jayne, D R
Format: Article
Language:English
Subjects:
Patients
Rheumatoid arthritis
Tumor necrosis factor-TNF
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Blockade of tumour necrosis factor alpha (TNFα) using infliximab, a chimeric monoclonal antibody against TNFα, is an effective treatment in rheumatoid arthritis and Crohn's disease. 1, 2 Sifikakis reported success using infliximab in sight threatening Behcet's disease. 3 A preliminary study has also reported clinical improvements in the primary systemic vasculitis, Wegener's granulomatosis, with the soluble TNFα receptor etanercept. 4 The benefit of lenercept, a soluble p55 TNFα receptor fusion protein, on digital vasculitis in rheumatoid arthritis has also been reported. 5 We report the compassionate treatment of six patients with refractory vasculitis using infliximab.
ISSN:0003-4967
1468-2060
DOI:10.1136/ard.61.6.559